vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Trip.com Group Ltd (TCOM). Click either name above to swap in a different company.
Trip.com Group Ltd is the larger business by last-quarter revenue ($304.6M vs $191.2M, roughly 1.6× Axsome Therapeutics, Inc.).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Trip.com Group Limited is a multinational travel agency headquartered in Shanghai, China. It is the largest online travel service provider in the world.
AXSM vs TCOM — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $304.6M |
| Net Profit | — | $84.6M |
| Gross Margin | — | 78.8% |
| Operating Margin | -33.1% | 16.5% |
| Net Margin | — | 27.8% |
| Revenue YoY | 57.4% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $304.6M | ||
| Q3 25 | $171.0M | — | ||
| Q2 25 | $150.0M | — | ||
| Q1 25 | $121.5M | — | ||
| Q4 24 | $118.8M | — | ||
| Q3 24 | $104.8M | — | ||
| Q2 24 | $87.2M | $242.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $84.6M | ||
| Q3 25 | $-47.2M | — | ||
| Q2 25 | $-48.0M | — | ||
| Q1 25 | $-59.4M | — | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | — | ||
| Q2 24 | $-79.3M | $73.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 78.8% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 81.8% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 16.5% | ||
| Q3 25 | -27.0% | — | ||
| Q2 25 | -24.5% | — | ||
| Q1 25 | -46.9% | — | ||
| Q4 24 | -61.1% | — | ||
| Q3 24 | -59.8% | — | ||
| Q2 24 | -89.5% | 27.8% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | 27.8% | ||
| Q3 25 | -27.6% | — | ||
| Q2 25 | -32.0% | — | ||
| Q1 25 | -48.9% | — | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | — | ||
| Q2 24 | -91.0% | 30.4% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $0.12 | ||
| Q3 25 | $-0.94 | — | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | — | ||
| Q2 24 | $-1.67 | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $10.8B |
| Total DebtLower is stronger | $70.0M | $4.2B |
| Stockholders' EquityBook value | — | $23.8B |
| Total Assets | $713.6M | $36.9B |
| Debt / EquityLower = less leverage | — | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $10.8B | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | $12.4B |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $4.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $8.2B |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $23.8B | ||
| Q3 25 | $73.7M | — | ||
| Q2 25 | $73.1M | — | ||
| Q1 25 | $53.2M | — | ||
| Q4 24 | $57.0M | — | ||
| Q3 24 | $92.9M | — | ||
| Q2 24 | $102.9M | $18.1B |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $36.9B | ||
| Q3 25 | $669.3M | — | ||
| Q2 25 | $639.8M | — | ||
| Q1 25 | $596.7M | — | ||
| Q4 24 | $568.5M | — | ||
| Q3 24 | $561.5M | — | ||
| Q2 24 | $548.2M | $34.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.18× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.45× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
TCOM
| Others | $273.0M | 90% |
| Other | $31.6M | 10% |
